Click for best price
Multiple Sclerosis MS Drugs Market Size, Share 2022
This report contains market size and forecasts of Multiple Sclerosis (MS) Drugs in global, including the following market information:
Global Multiple Sclerosis (MS) Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Multiple Sclerosis (MS) Drugs Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Multiple Sclerosis (MS) Drugs companies in 2021 (%)
The global Multiple Sclerosis (MS) Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Copaxone (Glatiramer Acetate, Copolymer 1) Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Multiple Sclerosis (MS) Drugs include Bayer AG, Bayhill Therapeutics, Biogen Idec, Cinnagen, Daiichi Sankyo, Eli Lilly, Fast Forward Llc, Antisense Therapeutics and Apitope, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Multiple Sclerosis (MS) Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Multiple Sclerosis (MS) Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Multiple Sclerosis (MS) Drugs Market Segment Percentages, by Type, 2021 (%)
Copaxone (Glatiramer Acetate, Copolymer 1)
Novantrone (Mitoxantrone)
Gilenya (Fingolimod, Fty720)
Aubagio (Teriflunomide)
Tecfidera (Dimethyl Fumarate)
Firategrast (Sb683699, T-0047)
Siponimod (Baf312)
Others
Global Multiple Sclerosis (MS) Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Multiple Sclerosis (MS) Drugs Market Segment Percentages, by Application, 2021 (%)
RRMS
SPMS
PPMS
PRMS
Global Multiple Sclerosis (MS) Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Multiple Sclerosis (MS) Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Multiple Sclerosis (MS) Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Multiple Sclerosis (MS) Drugs revenues share in global market, 2021 (%)
Key companies Multiple Sclerosis (MS) Drugs sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Multiple Sclerosis (MS) Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bayer AG
Bayhill Therapeutics
Biogen Idec
Cinnagen
Daiichi Sankyo
Eli Lilly
Fast Forward Llc
Antisense Therapeutics
Apitope
Five Prime Therapeutics
Genmab
Artielle Immunotherapeutics
Genzyme
Glaxosmithkline
Gw Pharmaceuticals
Innate Immunotherapeutics
| Report Attributes |
Report Details |
| Report Title |
Multiple Sclerosis (MS) Drugs Market, Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
111 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Multiple Sclerosis (MS) Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Multiple Sclerosis (MS) Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Multiple Sclerosis (MS) Drugs Overall Market Size
2.1 Global Multiple Sclerosis (MS) Drugs Market Size: 2021 VS 2028
2.2 Global Multiple Sclerosis (MS) Drugs Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Multiple Sclerosis (MS) Drugs Sales: 2017-2028
3 Company Landscape
3.1 Top Multiple Sclerosis (MS) Drugs Players in Global Market
3.2 Top Global Multiple Sclerosis (MS) Drugs Companies Ranked by Revenue
3.3 Global Multiple Sclerosis (MS) Drugs Revenue by Companies
3.4 Global Multiple Sclerosis (MS) Drugs Sales by Companies
3.5 Global Multiple Sclerosis (MS) Drugs Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Multiple Sclerosis (MS) Drugs Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Multiple Sclerosis (MS) Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Multiple Sclerosis (MS) Drugs Players in Global Market
3.8.1 List of Global Tier 1 Multiple Sclerosis (MS) Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Multiple Sclerosis (MS) Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Multiple Sclerosis (MS) Drugs Market Size Markets, 2021 & 2028
4.1.2 Copaxone (Glatiramer Acetate, Copolymer 1)
4.1.3 Novantrone (Mitoxantrone)
4.1.4 Gilenya (Fingolimod, Fty720)
4.1.5 Aubagio (Teriflunomide)
4.1.6 Tecfidera (Dimethyl Fumarate)
4.1.7 Firategrast (Sb683699, T-0047)
4.1.8 Siponimod (Baf312)
4.1.9 Others
4.2 By Type - Global Multiple Sclerosis (MS) Drugs Revenue & Forecasts
4.2.1 By Type - Global Multiple Sclerosis (MS) Drugs Revenue, 2017-2022
4.2.2 By Type - Global Multiple Sclerosis (MS) Drugs Revenue, 2023-2028
4.2.3 By Type - Global Multiple Sclerosis (MS) Drugs Revenue Market Share, 2017-2028
4.3 By Type - Global Multiple Sclerosis (MS) Drugs Sales & Forecasts
4.3.1 By Type - Global Multiple Sclerosis (MS) Drugs Sales, 2017-2022
4.3.2 By Type - Global Multiple Sclerosis (MS) Drugs Sales, 2023-2028
4.3.3 By Type - Global Multiple Sclerosis (MS) Drugs Sales Market Share, 2017-2028
4.4 By Type - Global Multiple Sclerosis (MS) Drugs Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application - Global Multiple Sclerosis (MS) Drugs Market Size, 2021 & 2028
5.1.2 RRMS
5.1.3 SPMS
5.1.4 PPMS
5.1.5 PRMS
5.2 By Application - Global Multiple Sclerosis (MS) Drugs Revenue & Forecasts
5.2.1 By Application - Global Multiple Sclerosis (MS) Drugs Revenue, 2017-2022
5.2.2 By Application - Global Multiple Sclerosis (MS) Drugs Revenue, 2023-2028
5.2.3 By Application - Global Multiple Sclerosis (MS) Drugs Revenue Market Share, 2017-2028
5.3 By Application - Global Multiple Sclerosis (MS) Drugs Sales & Forecasts
5.3.1 By Application - Global Multiple Sclerosis (MS) Drugs Sales, 2017-2022
5.3.2 By Application - Global Multiple Sclerosis (MS) Drugs Sales, 2023-2028
5.3.3 By Application - Global Multiple Sclerosis (MS) Drugs Sales Market Share, 2017-2028
5.4 By Application - Global Multiple Sclerosis (MS) Drugs Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region - Global Multiple Sclerosis (MS) Drugs Market Size, 2021 & 2028
6.2 By Region - Global Multiple Sclerosis (MS) Drugs Revenue & Forecasts
6.2.1 By Region - Global Multiple Sclerosis (MS) Drugs Revenue, 2017-2022
6.2.2 By Region - Global Multiple Sclerosis (MS) Drugs Revenue, 2023-2028
6.2.3 By Region - Global Multiple Sclerosis (MS) Drugs Revenue Market Share, 2017-2028
6.3 By Region - Global Multiple Sclerosis (MS) Drugs Sales & Forecasts
6.3.1 By Region - Global Multiple Sclerosis (MS) Drugs Sales, 2017-2022
6.3.2 By Region - Global Multiple Sclerosis (MS) Drugs Sales, 2023-2028
6.3.3 By Region - Global Multiple Sclerosis (MS) Drugs Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Multiple Sclerosis (MS) Drugs Revenue, 2017-2028
6.4.2 By Country - North America Multiple Sclerosis (MS) Drugs Sales, 2017-2028
6.4.3 US Multiple Sclerosis (MS) Drugs Market Size, 2017-2028
6.4.4 Canada Multiple Sclerosis (MS) Drugs Market Size, 2017-2028
6.4.5 Mexico Multiple Sclerosis (MS) Drugs Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Multiple Sclerosis (MS) Drugs Revenue, 2017-2028
6.5.2 By Country - Europe Multiple Sclerosis (MS) Drugs Sales, 2017-2028
6.5.3 Germany Multiple Sclerosis (MS) Drugs Market Size, 2017-2028
6.5.4 France Multiple Sclerosis (MS) Drugs Market Size, 2017-2028
6.5.5 U.K. Multiple Sclerosis (MS) Drugs Market Size, 2017-2028
6.5.6 Italy Multiple Sclerosis (MS) Drugs Market Size, 2017-2028
6.5.7 Russia Multiple Sclerosis (MS) Drugs Market Size, 2017-2028
6.5.8 Nordic Countries Multiple Sclerosis (MS) Drugs Market Size, 2017-2028
6.5.9 Benelux Multiple Sclerosis (MS) Drugs Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Multiple Sclerosis (MS) Drugs Revenue, 2017-2028
6.6.2 By Region - Asia Multiple Sclerosis (MS) Drugs Sales, 2017-2028
6.6.3 China Multiple Sclerosis (MS) Drugs Market Size, 2017-2028
6.6.4 Japan Multiple Sclerosis (MS) Drugs Market Size, 2017-2028
6.6.5 South Korea Multiple Sclerosis (MS) Drugs Market Size, 2017-2028
6.6.6 Southeast Asia Multiple Sclerosis (MS) Drugs Market Size, 2017-2028
6.6.7 India Multiple Sclerosis (MS) Drugs Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Multiple Sclerosis (MS) Drugs Revenue, 2017-2028
6.7.2 By Country - South America Multiple Sclerosis (MS) Drugs Sales, 2017-2028
6.7.3 Brazil Multiple Sclerosis (MS) Drugs Market Size, 2017-2028
6.7.4 Argentina Multiple Sclerosis (MS) Drugs Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Multiple Sclerosis (MS) Drugs Sales, 2017-2028
6.8.3 Turkey Multiple Sclerosis (MS) Drugs Market Size, 2017-2028
6.8.4 Israel Multiple Sclerosis (MS) Drugs Market Size, 2017-2028
6.8.5 Saudi Arabia Multiple Sclerosis (MS) Drugs Market Size, 2017-2028
6.8.6 UAE Multiple Sclerosis (MS) Drugs Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 Bayer AG
7.1.1 Bayer AG Corporate Summary
7.1.2 Bayer AG Business Overview
7.1.3 Bayer AG Multiple Sclerosis (MS) Drugs Major Product Offerings
7.1.4 Bayer AG Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2017-2022)
7.1.5 Bayer AG Key News
7.2 Bayhill Therapeutics
7.2.1 Bayhill Therapeutics Corporate Summary
7.2.2 Bayhill Therapeutics Business Overview
7.2.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Major Product Offerings
7.2.4 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2017-2022)
7.2.5 Bayhill Therapeutics Key News
7.3 Biogen Idec
7.3.1 Biogen Idec Corporate Summary
7.3.2 Biogen Idec Business Overview
7.3.3 Biogen Idec Multiple Sclerosis (MS) Drugs Major Product Offerings
7.3.4 Biogen Idec Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2017-2022)
7.3.5 Biogen Idec Key News
7.4 Cinnagen
7.4.1 Cinnagen Corporate Summary
7.4.2 Cinnagen Business Overview
7.4.3 Cinnagen Multiple Sclerosis (MS) Drugs Major Product Offerings
7.4.4 Cinnagen Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2017-2022)
7.4.5 Cinnagen Key News
7.5 Daiichi Sankyo
7.5.1 Daiichi Sankyo Corporate Summary
7.5.2 Daiichi Sankyo Business Overview
7.5.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Major Product Offerings
7.5.4 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2017-2022)
7.5.5 Daiichi Sankyo Key News
7.6 Eli Lilly
7.6.1 Eli Lilly Corporate Summary
7.6.2 Eli Lilly Business Overview
7.6.3 Eli Lilly Multiple Sclerosis (MS) Drugs Major Product Offerings
7.6.4 Eli Lilly Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2017-2022)
7.6.5 Eli Lilly Key News
7.7 Fast Forward Llc
7.7.1 Fast Forward Llc Corporate Summary
7.7.2 Fast Forward Llc Business Overview
7.7.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Major Product Offerings
7.7.4 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2017-2022)
7.7.5 Fast Forward Llc Key News
7.8 Antisense Therapeutics
7.8.1 Antisense Therapeutics Corporate Summary
7.8.2 Antisense Therapeutics Business Overview
7.8.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Major Product Offerings
7.8.4 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2017-2022)
7.8.5 Antisense Therapeutics Key News
7.9 Apitope
7.9.1 Apitope Corporate Summary
7.9.2 Apitope Business Overview
7.9.3 Apitope Multiple Sclerosis (MS) Drugs Major Product Offerings
7.9.4 Apitope Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2017-2022)
7.9.5 Apitope Key News
7.10 Five Prime Therapeutics
7.10.1 Five Prime Therapeutics Corporate Summary
7.10.2 Five Prime Therapeutics Business Overview
7.10.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Major Product Offerings
7.10.4 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2017-2022)
7.10.5 Five Prime Therapeutics Key News
7.11 Genmab
7.11.1 Genmab Corporate Summary
7.11.2 Genmab Multiple Sclerosis (MS) Drugs Business Overview
7.11.3 Genmab Multiple Sclerosis (MS) Drugs Major Product Offerings
7.11.4 Genmab Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2017-2022)
7.11.5 Genmab Key News
7.12 Artielle Immunotherapeutics
7.12.1 Artielle Immunotherapeutics Corporate Summary
7.12.2 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Business Overview
7.12.3 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Major Product Offerings
7.12.4 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2017-2022)
7.12.5 Artielle Immunotherapeutics Key News
7.13 Genzyme
7.13.1 Genzyme Corporate Summary
7.13.2 Genzyme Multiple Sclerosis (MS) Drugs Business Overview
7.13.3 Genzyme Multiple Sclerosis (MS) Drugs Major Product Offerings
7.13.4 Genzyme Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2017-2022)
7.13.5 Genzyme Key News
7.14 Glaxosmithkline
7.14.1 Glaxosmithkline Corporate Summary
7.14.2 Glaxosmithkline Business Overview
7.14.3 Glaxosmithkline Multiple Sclerosis (MS) Drugs Major Product Offerings
7.14.4 Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2017-2022)
7.14.5 Glaxosmithkline Key News
7.15 Gw Pharmaceuticals
7.15.1 Gw Pharmaceuticals Corporate Summary
7.15.2 Gw Pharmaceuticals Business Overview
7.15.3 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Major Product Offerings
7.15.4 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2017-2022)
7.15.5 Gw Pharmaceuticals Key News
7.16 Innate Immunotherapeutics
7.16.1 Innate Immunotherapeutics Corporate Summary
7.16.2 Innate Immunotherapeutics Business Overview
7.16.3 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Major Product Offerings
7.16.4 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2017-2022)
7.16.5 Innate Immunotherapeutics Key News
8 Global Multiple Sclerosis (MS) Drugs Production Capacity, Analysis
8.1 Global Multiple Sclerosis (MS) Drugs Production Capacity, 2017-2028
8.2 Multiple Sclerosis (MS) Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Multiple Sclerosis (MS) Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Multiple Sclerosis (MS) Drugs Supply Chain Analysis
10.1 Multiple Sclerosis (MS) Drugs Industry Value Chain
10.2 Multiple Sclerosis (MS) Drugs Upstream Market
10.3 Multiple Sclerosis (MS) Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Multiple Sclerosis (MS) Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Multiple Sclerosis (MS) Drugs in Global Market
Table 2. Top Multiple Sclerosis (MS) Drugs Players in Global Market, Ranking by Revenue (2021)
Table 3. Global Multiple Sclerosis (MS) Drugs Revenue by Companies, (US$, Mn), 2017-2022
Table 4. Global Multiple Sclerosis (MS) Drugs Revenue Share by Companies, 2017-2022
Table 5. Global Multiple Sclerosis (MS) Drugs Sales by Companies, (K Pcs), 2017-2022
Table 6. Global Multiple Sclerosis (MS) Drugs Sales Share by Companies, 2017-2022
Table 7. Key Manufacturers Multiple Sclerosis (MS) Drugs Price (2017-2022) & (USD/Pcs)
Table 8. Global Manufacturers Multiple Sclerosis (MS) Drugs Product Type
Table 9. List of Global Tier 1 Multiple Sclerosis (MS) Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Multiple Sclerosis (MS) Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Global Multiple Sclerosis (MS) Drugs Revenue (US$, Mn), 2017-2022
Table 13. By Type - Global Multiple Sclerosis (MS) Drugs Revenue (US$, Mn), 2023-2028
Table 14. By Type - Global Multiple Sclerosis (MS) Drugs Sales (K Pcs), 2017-2022
Table 15. By Type - Global Multiple Sclerosis (MS) Drugs Sales (K Pcs), 2023-2028
Table 16. By Application ? Global Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2021 & 2028
Table 17. By Application - Global Multiple Sclerosis (MS) Drugs Revenue (US$, Mn), 2017-2022
Table 18. By Application - Global Multiple Sclerosis (MS) Drugs Revenue (US$, Mn), 2023-2028
Table 19. By Application - Global Multiple Sclerosis (MS) Drugs Sales (K Pcs), 2017-2022
Table 20. By Application - Global Multiple Sclerosis (MS) Drugs Sales (K Pcs), 2023-2028
Table 21. By Region ? Global Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2021 VS 2028
Table 22. By Region - Global Multiple Sclerosis (MS) Drugs Revenue (US$, Mn), 2017-2022
Table 23. By Region - Global Multiple Sclerosis (MS) Drugs Revenue (US$, Mn), 2023-2028
Table 24. By Region - Global Multiple Sclerosis (MS) Drugs Sales (K Pcs), 2017-2022
Table 25. By Region - Global Multiple Sclerosis (MS) Drugs Sales (K Pcs), 2023-2028
Table 26. By Country - North America Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2022
Table 27. By Country - North America Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2023-2028
Table 28. By Country - North America Multiple Sclerosis (MS) Drugs Sales, (K Pcs), 2017-2022
Table 29. By Country - North America Multiple Sclerosis (MS) Drugs Sales, (K Pcs), 2023-2028
Table 30. By Country - Europe Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2022
Table 31. By Country - Europe Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2023-2028
Table 32. By Country - Europe Multiple Sclerosis (MS) Drugs Sales, (K Pcs), 2017-2022
Table 33. By Country - Europe Multiple Sclerosis (MS) Drugs Sales, (K Pcs), 2023-2028
Table 34. By Region - Asia Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2022
Table 35. By Region - Asia Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2023-2028
Table 36. By Region - Asia Multiple Sclerosis (MS) Drugs Sales, (K Pcs), 2017-2022
Table 37. By Region - Asia Multiple Sclerosis (MS) Drugs Sales, (K Pcs), 2023-2028
Table 38. By Country - South America Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2022
Table 39. By Country - South America Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2023-2028
Table 40. By Country - South America Multiple Sclerosis (MS) Drugs Sales, (K Pcs), 2017-2022
Table 41. By Country - South America Multiple Sclerosis (MS) Drugs Sales, (K Pcs), 2023-2028
Table 42. By Country - Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2022
Table 43. By Country - Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2023-2028
Table 44. By Country - Middle East & Africa Multiple Sclerosis (MS) Drugs Sales, (K Pcs), 2017-2022
Table 45. By Country - Middle East & Africa Multiple Sclerosis (MS) Drugs Sales, (K Pcs), 2023-2028
Table 46. Bayer AG Corporate Summary
Table 47. Bayer AG Multiple Sclerosis (MS) Drugs Product Offerings
Table 48. Bayer AG Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 49. Bayhill Therapeutics Corporate Summary
Table 50. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Offerings
Table 51. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 52. Biogen Idec Corporate Summary
Table 53. Biogen Idec Multiple Sclerosis (MS) Drugs Product Offerings
Table 54. Biogen Idec Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 55. Cinnagen Corporate Summary
Table 56. Cinnagen Multiple Sclerosis (MS) Drugs Product Offerings
Table 57. Cinnagen Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 58. Daiichi Sankyo Corporate Summary
Table 59. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Offerings
Table 60. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 61. Eli Lilly Corporate Summary
Table 62. Eli Lilly Multiple Sclerosis (MS) Drugs Product Offerings
Table 63. Eli Lilly Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 64. Fast Forward Llc Corporate Summary
Table 65. Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Offerings
Table 66. Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 67. Antisense Therapeutics Corporate Summary
Table 68. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Offerings
Table 69. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 70. Apitope Corporate Summary
Table 71. Apitope Multiple Sclerosis (MS) Drugs Product Offerings
Table 72. Apitope Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 73. Five Prime Therapeutics Corporate Summary
Table 74. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Offerings
Table 75. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 76. Genmab Corporate Summary
Table 77. Genmab Multiple Sclerosis (MS) Drugs Product Offerings
Table 78. Genmab Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 79. Artielle Immunotherapeutics Corporate Summary
Table 80. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Offerings
Table 81. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 82. Genzyme Corporate Summary
Table 83. Genzyme Multiple Sclerosis (MS) Drugs Product Offerings
Table 84. Genzyme Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 85. Glaxosmithkline Corporate Summary
Table 86. Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Offerings
Table 87. Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 88. Gw Pharmaceuticals Corporate Summary
Table 89. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Offerings
Table 90. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 91. Innate Immunotherapeutics Corporate Summary
Table 92. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Offerings
Table 93. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 94. Multiple Sclerosis (MS) Drugs Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2020-2022 (K Pcs)
Table 95. Global Multiple Sclerosis (MS) Drugs Capacity Market Share of Key Manufacturers, 2020-2022
Table 96. Global Multiple Sclerosis (MS) Drugs Production by Region, 2017-2022 (K Pcs)
Table 97. Global Multiple Sclerosis (MS) Drugs Production by Region, 2023-2028 (K Pcs)
Table 98. Multiple Sclerosis (MS) Drugs Market Opportunities & Trends in Global Market
Table 99. Multiple Sclerosis (MS) Drugs Market Drivers in Global Market
Table 100. Multiple Sclerosis (MS) Drugs Market Restraints in Global Market
Table 101. Multiple Sclerosis (MS) Drugs Raw Materials
Table 102. Multiple Sclerosis (MS) Drugs Raw Materials Suppliers in Global Market
Table 103. Typical Multiple Sclerosis (MS) Drugs Downstream
Table 104. Multiple Sclerosis (MS) Drugs Downstream Clients in Global Market
Table 105. Multiple Sclerosis (MS) Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Multiple Sclerosis (MS) Drugs Segment by Type
Figure 2. Multiple Sclerosis (MS) Drugs Segment by Application
Figure 3. Global Multiple Sclerosis (MS) Drugs Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Multiple Sclerosis (MS) Drugs Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Multiple Sclerosis (MS) Drugs Revenue, 2017-2028 (US$, Mn)
Figure 7. Multiple Sclerosis (MS) Drugs Sales in Global Market: 2017-2028 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Multiple Sclerosis (MS) Drugs Revenue in 2021
Figure 9. By Type - Global Multiple Sclerosis (MS) Drugs Sales Market Share, 2017-2028
Figure 10. By Type - Global Multiple Sclerosis (MS) Drugs Revenue Market Share, 2017-2028
Figure 11. By Type - Global Multiple Sclerosis (MS) Drugs Price (USD/Pcs), 2017-2028
Figure 12. By Application - Global Multiple Sclerosis (MS) Drugs Sales Market Share, 2017-2028
Figure 13. By Application - Global Multiple Sclerosis (MS) Drugs Revenue Market Share, 2017-2028
Figure 14. By Application - Global Multiple Sclerosis (MS) Drugs Price (USD/Pcs), 2017-2028
Figure 15. By Region - Global Multiple Sclerosis (MS) Drugs Sales Market Share, 2017-2028
Figure 16. By Region - Global Multiple Sclerosis (MS) Drugs Revenue Market Share, 2017-2028
Figure 17. By Country - North America Multiple Sclerosis (MS) Drugs Revenue Market Share, 2017-2028
Figure 18. By Country - North America Multiple Sclerosis (MS) Drugs Sales Market Share, 2017-2028
Figure 19. US Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2028
Figure 20. Canada Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2028
Figure 21. Mexico Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2028
Figure 22. By Country - Europe Multiple Sclerosis (MS) Drugs Revenue Market Share, 2017-2028
Figure 23. By Country - Europe Multiple Sclerosis (MS) Drugs Sales Market Share, 2017-2028
Figure 24. Germany Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2028
Figure 25. France Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2028
Figure 26. U.K. Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2028
Figure 27. Italy Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2028
Figure 28. Russia Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2028
Figure 29. Nordic Countries Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2028
Figure 30. Benelux Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2028
Figure 31. By Region - Asia Multiple Sclerosis (MS) Drugs Revenue Market Share, 2017-2028
Figure 32. By Region - Asia Multiple Sclerosis (MS) Drugs Sales Market Share, 2017-2028
Figure 33. China Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2028
Figure 34. Japan Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2028
Figure 35. South Korea Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2028
Figure 36. Southeast Asia Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2028
Figure 37. India Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2028
Figure 38. By Country - South America Multiple Sclerosis (MS) Drugs Revenue Market Share, 2017-2028
Figure 39. By Country - South America Multiple Sclerosis (MS) Drugs Sales Market Share, 2017-2028
Figure 40. Brazil Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2028
Figure 41. Argentina Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2028
Figure 42. By Country - Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue Market Share, 2017-2028
Figure 43. By Country - Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Market Share, 2017-2028
Figure 44. Turkey Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2028
Figure 45. Israel Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2028
Figure 46. Saudi Arabia Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2028
Figure 47. UAE Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2017-2028
Figure 48. Global Multiple Sclerosis (MS) Drugs Production Capacity (K Pcs), 2017-2028
Figure 49. The Percentage of Production Multiple Sclerosis (MS) Drugs by Region, 2021 VS 2028
Figure 50. Multiple Sclerosis (MS) Drugs Industry Value Chain
Figure 51. Marketing Channels
